Teva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette Syndrome

Teva presented new efficacy and safety data for ecopipam, an investigational first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. The update supports continued development of Teva's neurology pipeline, though the article provides no trial efficacy figures, safety details, regulatory milestones, or commercial guidance.